Vivo Capital is a global healthcare investment firm that has been investing for over 20 years. Our investments across multiple funds and strategies are driven by a value and growth-oriented investment strategy, combined with extensive medical and scientific expertise.
Vivo is currently making investments from its $1.4B Vivo Capital Fund IX into private healthcare companies, from its $635M Vivo Opportunity Fund into public healthcare companies, and from its $100M Vivo Innovation (PANDA) Fund into early-stage innovative healthcare companies.
Vivo’s Three Fund Vehicles
Private Equity
Vivo Capital Fund IX and its predecessor funds are growth capital and private equity-focused investment vehicles investing in the healthcare industry. Vivo invests in product-driven companies that develop and commercialize therapeutics, including pharmaceuticals, biotechnology and medical devices. Our growth capital investments help our portfolio companies accelerate revenue ramp or fund product development to drive value creation. Our private equity investments focus primarily on buyouts, privatizations, and spin-off opportunities. We invest in structures ranging from minority equity investments to control transactions with a primary focus on the U.S. and Greater China.
Public Equity
Vivo Opportunity Fund primarily invests in the global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies. The fund is long only and often invests directly into companies through various financing structures, including follow-ons, secondaries, PIPEs, ATM purchases, and IPOs.
Our Portfolio
News
-
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China GalleryVISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
